Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
Akums and TNAU will collaborate to strengthen research through shared expertise and innovative agricultural solutions, to foster innovation in formulation development
Branded formulation business continues to perform well across domestic and export markets
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
Akums Drugs will undertake this development and commercialization in India
e brings over 27+ years of rich pharmaceutical experience
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
Subscribe To Our Newsletter & Stay Updated
